European Commission has granted Orphan Medicinal Product Designation to Alexion’s Soliris (eculizumab), for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). Alexion is currently enrolling patients
Bellicum has initiated dosing of the first patient in a phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate
ViroPharma has initiated dosing in the phase 1 clinical trial for NTCD (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections (CDI). The phase
NPS Pharmaceuticals has reported net income of $2.6 million or $0.05 per diluted share, for the second quarter of 2009, compared to net income of $1.2 million or
King Pharmaceuticals has submitted a briefing package to FDA addressing the issues raised in the Agency’s June 30 Complete Response Letter (CRL), related to the New Drug Application
Emergent BioSolutions has executed multiple real estate transactions that will expand the company’s manufacturing and development infrastructure. The company expects that these transactions would broaden its manufacturing options.
Alzheimer’s Drug Discovery Foundation (ADDF) has announced that the new therapeutics, developed by PharmatrophiX, has entered into a significant milestone in its development. ADDF also announced that PharmatrophiX
Spectrum (SPPI) has acquired 100% rights to RenaZorb (RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications. The acquisition
Elan has filed suit against Biogen Idec in Federal Court in New York. Elan is seeking declaratory and injunctive relief that certain aspects of its transaction with affiliates
Amgen has reported that Vectibix (panitumumab), administered in combination with Folfox (an oxaliplatin-based chemotherapy), prolonged progression-free survival (PFS), as compared to Folfox alone in the treatment of KRAS
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.